UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME

Rhea-AI Summary

UNITY Biotechnology (Nasdaq: UBX) will host an investor call on August 12, 2022, at 5:00 a.m. PT/8:00 a.m. ET, featuring retinal expert Robert Bhisitkul, M.D., Ph.D. The discussion will center around its lead program, UBX1325, aimed at developing therapies targeting age-related diseases. The call will be accessible via their website, with a replay available shortly after. UNITY is focused on innovative therapeutics to combat aging diseases by eliminating senescent cells, with implications for ophthalmologic and neurologic conditions.

Positive

• Investor call focused on lead program UBX1325 indicates ongoing development and transparency with stakeholders.
• Collaboration with retinal expert Robert Bhisitkul may enhance credibility and insight into the program's potential.

Negative

• None.

Investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., to be held on Friday, August 12 at 5:00 a.m. PT/8:00 a.m. ET

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an investor call to discuss lead program, UBX1325 on Friday, August 12, 2022 at 5:00 a.m. ET/8:00 a.m. ET, with retinal expert Robert Bhisitkul, M.D., Ph.D., Professor of Ophthalmology, UCSF.

The live webcast can be accessed in the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations” or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the “Investors & Media” section of our website, under “Events and Presentations.”

About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media Contact:
Evoke Canale
Katherine Smith
Katherine.Smith@evokegroup.com

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Source: Unity Biotechnology, Inc

FAQ

What is the purpose of UNITY Biotechnology's upcoming investor call on August 12, 2022?

The call will discuss UNITY's lead program, UBX1325, focusing on therapeutics aimed at age-related diseases.

Who will be presenting during the investor call for UBX?

Retinal expert Robert Bhisitkul, M.D., Ph.D., will present during the call.

How can investors access the investor call for UNITY Biotechnology?

Investors can access the call on UNITY's website under the 'Investors and Media' section or directly through the Events & Presentations page.

What is the significance of UBX1325 in UNITY Biotechnology's pipeline?

UBX1325 is aimed at addressing age-related ophthalmologic diseases, signaling UNITY's focus on innovative solutions for aging-related conditions.